Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
James Wilson
BioCentury | Aug 6, 2024
Deals
Biotech-academia deals, Leqembi’s latest data and what’s next for James Wilson: a BioCentury podcast
Small companies seeking pipeline solutions from academics far from biotech hubs. Standout Leqembi data. What’s next for Wilson after Penn
BioCentury | Aug 2, 2024
Management Tracks
James Wilson, gene therapy trailblazer, exits Penn to launch two newcos
Plus: Myriad hires Jennifer Fox as chief legal officer, and updates from Odyssey, Enveda and Accelerated Cure Project
BioCentury | May 17, 2022
Politics, Policy & Law
FDA bolstering rare disease oversight
Advocates pressing for more, including center of excellence
BioCentury | Sep 29, 2021
Deals
Amicus’ Crowley to lead gene therapy spinout after SPAC deal
Amicus will be largest shareholder in newly launched Caritas, which will advance genetic medicines pipeline
BioCentury | Sep 9, 2021
Emerging Company Profile
Wilson ventures into gene editing with iECURE launch, backed by $50M series A
Emerging Company Profile: OrbiMed, Versant back Jim Wilson’s latest launch, which applies gene editing to rare pediatric diseases
BioCentury | Aug 5, 2021
Finance
Tachi Yamada, R&D leader and global health advocate, passes away at 76
Yamada revamped R&D at GSK, Takeda, built companies at Frazier
BioCentury | May 18, 2021
Finance
May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Dec 5, 2020
Translation in Brief
James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more
BioCentury’s roundup of translational news
BioCentury | Oct 17, 2020
Translation in Brief
SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more
BioCentury’s roundup of translational news
BioCentury | Jun 6, 2020
Product Development
AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity
The rationale behind the only AAV-based vaccine in development for COVID-19
Items per page:
1 - 10 of 69